Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Obstetrics & Gynecology
Publication stageIn Press Journal Pre-Proof
Disclosure statement: Dr. Sentilhes reports receiving lecture and consulting fees from Ferring, and lecture fees from Bayer, GSK and SIGVARIS. Dr Daniel reports receiving lecture and consulting fees from LFB. No other potential conflict of interest relevant to this article was reported.
Funding Statement: The TRAAP2 trial was funded by the French Ministry of Health under its Clinical Research Hospital Program (PHRC, 2015, PHRC-15-0011).
Trial registration: ClinicalTrials.gov Identifier: NCT03431805.
Among women with a multiple pregnancy and cesarean delivery, prophylactic tranexamic acid did not reduce the incidence of any blood loss-related outcomes.
AJOG at a Glance:
A. Why was this study conducted?
The magnitude effect of prophylactic tranexamic acid at cesarean delivery is unknown in women at high risk of blood loss, including those with multiple pregnancies.
B. What are the key findings?
In this subgroup analysis of a multicenter, double-blind, randomized controlled trial (TRAAP2 trial) that included 319 women with multiple pregnancy, the rates of blood loss-related outcomes did not differ in the tranexamic acid group and the placebo group.
C. What does this study add to what is already known?
These findings do not support superiority of tranexamic acid over placebo for the reduction of any blood loss-related outcomes among women with a multiple pregnancy and cesarean delivery.